22Jan
Blog: Cooley’s 2020 Life Sciences M&A Year in Review
General Trends in Life Sciences M&A - If 2019 was the year of life sciences mega-deals, 2020 was the year of COVID-19, as the global pandemic permeated every aspect of the dealmaking landscape, with the life sciences sector being no exception. COVID-19 drove unprecedented levels of collaboration among biopharmaceutical companies seeking to develop a vaccine, leading to an accelerated research and development process that allowed not just one—but two—vaccines to be approved by the FDA in...
By:
Cooley LLP
Related
In this one-hour webcast, Wendy will help your understanding of how to best manage Independent Contr...
Read More >
In late 2019, COVID-19 (more commonly known as the coronavirus) began to spread throughout mainland ...
Read More >
In today’s edition of Daily Compliance News: What happens when you have an innovation and no one t...
Read More >
As cases of COVID-19 have started to spread throughout the United States, we have received a number ...
Read More >
California Governor Gavin Newsom signed groundbreaking legislation largely impacting mandatory arbit...
Read More >
I. International Case Law - The use of secret video surveillance can be regarded as proportionate ...
Read More >